Metacrine Announces Resignation of Chief Medical Officer
December 27 2021 - 8:00AM
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical
company pioneering differentiated therapies for patients with
gastrointestinal and liver diseases, today announced that Hubert C.
Chen, M.D., chief medical officer, has resigned to pursue a new
opportunity. Dr. Chen’s resignation is effective December 31, 2021.
Preston Klassen, M.D., MHS, chief executive officer, is expected to
assume responsibility for Metacrine’s ongoing clinical trials and
future clinical operations.
“We appreciate Hubert’s significant contributions during the
last three years as we moved our pipeline through several important
milestones,” said Preston Klassen, M.D., MHS, CEO, Metacrine.
“Hubert has established a strong team in our R&D organization
that will continue to serve us well as we focus our resources on
moving our IBD program into the clinic. We wish Hubert success in
his future endeavors.”
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company
building a pipeline of differentiated therapies to treat
gastrointestinal and liver diseases. Metacrine has developed a
proprietary farnesoid X receptor (FXR) platform utilizing a unique
chemical scaffold, which has demonstrated an improved therapeutic
profile in clinical trials. To learn more, visit
www.metacrine.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, statements about plans for
initiating future clinical trials and studies. Words such as “may,”
“will,” “expect,” “plan,” “aim,” “projected,” “likely,”
“anticipate,” “estimate,” “intend,” “potential,” “prepare,”
“perceived,” “believes” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Metacrine’s
expectations and assumptions that may never materialize or prove to
be incorrect. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from
those projected in any forward-looking statements due to numerous
risks and uncertainties, including but not limited to: risks and
uncertainties regarding regulatory approvals for MET409 or MET642;
potential delays in initiating, enrolling or completing any
clinical trials; potential adverse side effects or other safety
risks associated with Metacrine’s product candidates; competition
from third parties that are developing products for similar uses;
and Metacrine’s ability to obtain, maintain and protect its
intellectual property. Information regarding the foregoing and
additional risks may be found in the section entitled “Risk
Factors” in Metacrine’s Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission (the “SEC”) on November 12,
2021, and in Metacrine’s other filings with the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except as required by
law, Metacrine assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Investor & Media ContactSteve
KunszaboMetacrine, Inc.+1 (858) 369-7892
skunszabo@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Oct 2023 to Oct 2024